AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05507411 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Neoadjuvant Radiotherapy
Description: 41.4Gy/23F
Study NCT05507411 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Neoadjuvant Chemotherapy
Description: Paclitaxel for Injection （Albumin Bound): 50mg/m\^2 QW Carboplatin: AUC=2 QW
Study NCT05507411 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Immunotherapy
Description: Camrelizumab 200mg Q3W
Study NCT05942508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 Injection + Anlotinib Hydrochloride Capsules
Description: Anlotinib Hydrochloride Capsules: multi-target receptor tyrosine kinase inhibitor; TQB2450 injection: programmed cell death protein 1 (PD-1) human monoclonal antibody
Study NCT05802459 — intervention group
Intervention type: OTHER
Intervention: EORTC QLQ-C30
Description: central generic questionnaire associated with different disease specific modules
Study NCT05802459 — intervention group
Intervention type: OTHER
Intervention: EORTC QLQ-OG25
Description: module to assess the quality of life in patients with esophagogastric disease.
Study NCT05802459 — intervention group
Intervention type: OTHER
Intervention: GIQLI
Description: Gastrointestinal Quality of Life Index. It is a gastrointestinal quality of life scale.
Study NCT05802459 — intervention group
Intervention type: OTHER
Intervention: SWAL QoL
Description: Swallowing Quality of Life questionnaire. This is a quality of life and quality of attention questionnaire for patients with oropharyngeal dysphagia.
Study NCT05802459 — intervention group
Intervention type: PROCEDURE
Intervention: Videofluoroscopy
Description: It consists of 14 items that represent the oral and pharyngeal function observed in the VDF. It allows to quantify the severity of dysphagia.
Study NCT05653505 — intervention group
Intervention type: OTHER
Intervention: Remote Ischemic Conditioning
Description: Remote ischaemic conditioning (RIC) refers to a process whereby periods of intermittent ischemia, typically via the cyclical application of a blood pressure cuff to a limb at above systolic pressure, confers systemic protection against ischemia in spatially distinct vascular territories.
Study NCT05620758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nd YAG laser
Description: patients from those diagnosed with TMD will receive Nd YAG laser 1064 nm
Study NCT05620758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diode laser (980 nm)
Description: patients from those diagnosed with TMD will receive a diode laser (980 nm)
Study NCT05620758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diode laser (940 nm)
Description: patients from those diagnosed with TMD will receive a diode laser (940 nm)
Study NCT05620758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diode laser (660 nm)
Description: patients from those diagnosed with TMD will receive a diode laser (660 nm)
Study NCT05620758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diode laser (635 nm)
Description: patients from those diagnosed with TMD will receive a diode laser (635 nm)
Study NCT05479864 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: anterior cervical corpectomy and fusion
Description: removal of damaged vertebrae and intervertebral disc that are compressing the spinal cord and spinal nerves
Study NCT05151094 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation of clinical outcomes and comparison to non-treated patients
Study NCT06575478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuling Yunhua Granules
Description: Fuling Yunhua Granules
Study NCT06575478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fuling Yunhua Granules matched placebo
Description: Fuling Yunhua Granules placebo
Study NCT06575478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihuang Baoyuan Granules
Description: Dihuang Baoyuan Granules
Study NCT06575478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dihuang Baoyuan Granules matched placebo
Description: Dihuang Baoyuan Granules placebo
Study NCT05603871 — intervention group
Intervention type: PROCEDURE
Intervention: ligamentoplasty of ligamentum teres
Description: An addition to the steps of the open reduction, the following were done:~1. Identification of ligamentum teres~2. Ligamentoplasty of ligamentum teres
Study NCT06008652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bi-specific antibody
Study NCT06008652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04147052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSLEEPms
Description: Participants randomized to iSLEEPms complete daily online sleep diary forms and weekly online educational modules. Modules focus on typical elements of CBT-I, adapted for individuals with MS: education about sleep in MS, sleep restriction, and stimulus control; sleep hygiene and relaxation; and cognitive restructuring around sleep and coping with MS. Sleep diaries are scored each week, and feedback is provided to participants to guide adjustments to their recommended bedtimes and wake times. Telephone support is available to provide clarification around module content.
Study NCT04635904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal exposure one-session
Description: Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenarios multiple times while honing in on the most negative aspects.
Study NCT04635904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery rescriptinf one-session
Description: Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) o imagine a script based on a future distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery.
Study NCT06388083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinlarebant
Description: 5 mg tablet
Study NCT06388083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT06162520 — intervention group
Intervention type: OTHER
Intervention: Contrast-enhanced computed tomography (CECT) and 3D morphological analysis
Description: Diagnosis models are established using quantitative morphological characteristics extracted from the 3D reconstructed bile duct from contrast-enhanced computed tomography (CECT) images.
Study NCT06635343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPRP
Description: In the CPRP group, a chest physiotherapy program was given by the physiotherapist 5 days a week, for 8 weeks, including respiratory control, diaphragmatic breathing, thoracic expansion exercises, and physical activity recommendations, to be applied once a day.
Study NCT06635343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Inspiratuar Muscle Training
Description: In the experimental group inspiratory muscle training was applied. Children in the experimental group started inspiratory muscle training at 30% of the measured intra-oral maximum inspiratory pressure (MIP) value with 30x2 breaths (1 minute rest between repetitions) for 5 days a week for 8 weeks. The training was carried out with MIP every week. The training was continued for a total of 8 weeks with 30% of the new value by re-measuring the MIP value every week The value was measured again and continued at 30% of the new value for a total of 8 weeks. During each inspiratory muscle training session, oxygen saturation data from the index finger were monitored with a pulse oximeter to prevent individuals from experiencing hypoxia
Study NCT06634888 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Injectable platelet rich fbirin
Description: After the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. All patients in this study were submitted for Cone beam computed tomography (CBCT) scanning before and after canine retraction. Cone beam computed tomography (CBCT) was used before and four months after retraction, with imaging conducted using the Orthophos SL 3D X-ray machine (Dentsply Sirona, Charlotte, CA, USA) while adhering to As Low As Reasonably Achievable (ALARA) guidelines to minimize radiation exposure
Study NCT06634888 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Injectable platelet rich fbirin
Description: All patients in this study were submitted for Cone beam computed tomography (CBCT) scanning before and after canine retraction. Cone beam computed tomography (CBCT) was used before and four months after retraction, with imaging conducted using the Orthophos SL 3D X-ray machine (Dentsply Sirona, Charlotte, CA, USA) while adhering to As Low As Reasonably Achievable (ALARA) guidelines to minimize radiation exposure
Study NCT05584215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Psychosis Groups
Description: Groups based on cognitive behavioural therapy for psychosis
Study NCT05542355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXL01
Description: Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
Study NCT05542355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral EXL01 matching placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
Study NCT05542355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoC corticosteroid - Induction Period
Description: Oral prednisone 40 mg or budesonide 9 mg once daily for 3 to 7 weeks, as assigned by the investigator
Study NCT05542355 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SoC corticosteroid - Induction Period
Description: Oral prednisone 40 mg or budesonide 9 mg once daily for 3 to 7 weeks, as assigned by the investigator
Study NCT05542355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoC corticosteroid - Tapering
Description: Same product as the Induction Period.~Oral prednisone: 30 mg for 1 week, 25 mg for 1 week, 20 mg for 1 week, 15 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week and stop.~OR~Oral budesonide: 6 mg for 3 weeks, 3 mg for 3 weeks, stop.
Study NCT04340947 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Very low nicotine cigarettes
Description: Participants will be randomized to smoke menthol and non-menthol flavored very low nicotine cigarettes in their home environment for 7 days and in the laboratory
Study NCT04744194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic hamstring exercise program
Description: Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
Study NCT04744194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assisted nordic hamstring exercise program
Description: Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
Study NCT05925647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Messenchymal stem cell secretome
Description: Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
Study NCT05925647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0,9% infusion
Study NCT06537167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Description: Participants will receive proper transcutaneous electrical acupoint stimulation treatment for three consecutive days. Each day, the selected five target acupoints (Renying, Quchi, Taichong, Zusanli, and Hegu) will be stimulated in rotation. Each acupoint will be stimulated once a day for 10 minutes, with a 2-minute interval between each acupoint, totaling 60 minutes. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.
Study NCT05542355 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SoC corticosteroid - Tapering
Description: Same product as the Induction Period.~Oral prednisone: 30 mg for 1 week, 25 mg for 1 week, 20 mg for 1 week, 15 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week and stop.~OR~Oral budesonide: 6 mg for 3 weeks, 3 mg for 3 weeks, stop.
Study NCT06635408 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cystatin c
Description: a biomarker to assess renal function
Study NCT06457750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feeding, Lifestyle, Activity Goals (FLAGs) Digital Health Application
Description: Feeding, lifestyle, activity goals (FLAGs) is a digital assessment and advisory tool developed by the investigators to facilitate early identification of lifestyle behaviour problems and abnormal feeding patterns in infants, with real-time feedback for caregivers. The FLAGs questionnaire examines the domains of energy regulation, timeliness and adequacy of weaning, dietary practices, and lifestyle habits. Tailored recommendations have been developed for each domain accordingly. The objective of FLAGs is shaping healthy lifestyle and feeding behaviours from birth, charting a trajectory to optimal metabolic health.
Study NCT04639414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector
Description: Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d compared to matching placebo after 48-week treatment.
Study NCT04639414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide
Description: Measurement of the effect of empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
Study NCT04639414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching empagliflozin and placebo pen injector matching semaglutide
Description: Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d OR empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
Study NCT05954143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDC-1001
Description: BDC-1001 is an immune-stimulating antibody conjugate (ISAC) designed to be delivered systemically (intravenously) and act locally by targeting HER2-expressing tumors and related metastatic disease for destruction by the innate and adaptive immune systems. BDC-1001 consists of an investigational biosimilar of the humanized monoclonal antibody (mAb) trastuzumab that is chemically conjugated to a toll-like receptor (TLR)7/8 agonist (payload) with an intervening non-cleavable, cell membrane impermeable linker.
Study NCT05954143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab is a monoclonal antibody that targets HER2 and prevents dimerization of HER2 with other members of the HER family (HER1, HER3, and HER4), thereby blocking ligand-activated downstream signaling.
Study NCT06422741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: grape seed proanthocyanidin extract
Description: 250 mg of product presented in capsule form will be given.
Study NCT06422741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 165 mg of cellulose will be given presented in capsule form.
Study NCT06635083 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: A video conference software system will be installed on the subjects' laptops or tablets. Then, via video conference, strengthening/stretching exercises and breathing exercises will be performed for the areas affected by the deformity with the physiotherapist three times a week.
Study NCT06635083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: A video conference software system will be installed on the subjects' laptops or tablets. Then, via video conference, strengthening/stretching exercises and breathing exercises will be performed for the areas affected by the deformity with the physiotherapist three times a week.
Study NCT06635733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhapsode Capable™ Platform (Intervention Group)
Description: Participants in the intervention group will use the Rhapsode Capable™ platform to facilitate In-Person Skills Practice (ISP) sessions. The platform allows for scheduling ISP sessions, providing real-time performance feedback, and tracking progress. The platform integrates with the PACE adaptive learning modules, which cover pediatric acute care topics. The goal is to improve skills retention and performance in pediatric care through a blended learning approach.
Study NCT06537167 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Participants will receive sham stimulation treatment, where the left-side skin near the selected five target acupoints (avoiding other functional acupoints) will be stimulated in rotation. The stimulation time and method will be the same as in the experimental group. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.
Study NCT06290869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-based Tobacco Treatment, Nicotine Replacement, and Stepped Care Intervention
Description: In the MedStar Health System (MHS) arm, we offer 5 phone sessions with a tobacco treatment specialist (TTS) during the first 3 months of treatment plus combination nicotine replacement (patches and lozenges). For those who have not quit at 3 months, 50% will be randomly assigned to stepped care (3 phone sessions with RN/NP + prescription medications as needed) vs. the continued TTS + NRT intervention. Those who have quit at 3 months will be offered 3 relapse prevention phone sessions with the TTS. Thus, all are offered 8 sessions. The TTS will use motivational interviewing to address ambivalence about quitting, education about the risks of continued smoking, encouragement to use and adhere to NRT, and the impact of the screening result (the teachable moment) by framing it as a potential motivator or opportunity to reduce future health risks and to maximize quality of life.
Study NCT06290869 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-Referral to the Tobacco Quitline
Description: In the Quitline E-Referral arm, an e-referral will be generated from the EHR by our staff, will be signed by the LCS ordering provider and sent to the quitline through the closed-looped quitline's success.58-61,123 The quitline is an important comparator, given that it is an evidence-based and low-cost intervention already employed by many LCS sites system and the standard quitline protocol will then occur: 5 proactive contact attempts, up to 5 sessions, and up to 8 weeks of free NRT (depending on supplies). Quitline counselors are highly trained to conduct cessation treatment and extensive research has validated the quitline's success. The quitline is an important comparator, given that it is an evidence-based and low-cost intervention already employed by many LCS sites.
Study NCT06539806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 50mg Tab
Description: The efficacy of losartan on response rate in both metastatic and locally advanced pancreatic cancer patients
Study NCT06286410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bespoke glasses prescription worn during amblyopia treatment.
Description: The investigators aim to use the information they gather about a participant's accommodation response to be used in a bespoke glasses prescription that will be worn during amblyopia treatment. This is to try and improve vision in those with residual amblyopia following standard amblyopia treatment.
Study NCT06635733 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based ISP (Control Group)
Description: Participants in the control group will also receive In-Person Skills Practice (ISP) sessions facilitated by clinical champions, but without the use of the digital platform. The ISP sessions will be tracked and scheduled using paper-based assessments. Feedback will be provided verbally or manually, and progress will be documented using paper forms. Both groups will receive the same PACE adaptive learning modules, but the method of ISP implementation differs between the groups.
Study NCT04972500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricia Pre-op, 400 milliliters, per os
Description: After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
Study NCT05166018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SuMO Patient
Description: The current study is interventional insofar as the patient is collecting all of his socio-medical information. The analysis of the data provided by the patient makes it possible to establish a long-term prognosis for the patient but does not in itself constitute a parallel medical approach.~SUMO allows the surgeon to transmit post-operative advice developed by the surgeons themselves.